GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Rhea-AI Summary

GeneDx (WGS) reported strong Q3 2024 results with revenues of $76.6M, marking 52% year-over-year growth. The company achieved profitability with adjusted net income of $1.2M. Exome and genome test revenue grew 77% year-over-year to $60M, with test volume increasing 46% to 19,262. Adjusted gross margins expanded to 64%. The company raised its FY 2024 revenue guidance to $284-290M from previous $255-265M. GeneDx has conducted over 700,000 clinical exomes and genomes, with expanded coverage across 30 state Medicaid programs and growing presence in genomic newborn screening.

Positive

• Achieved profitability with $1.2M adjusted net income
• Revenue grew 52% YoY to $76.6M
• Exome and genome test revenue increased 77% YoY to $60M
• Adjusted gross margins improved to 64% from 48% YoY
• Raised FY 2024 revenue guidance to $284-290M
• Cash burn improved 88% YoY to $5.0M

Negative

• GAAP net loss of $8.3M
• Issued 418,653 new shares through ATM offering causing dilution

Insights

Financial Analyst

GeneDx delivered exceptional Q3 results, marking a pivotal transition to profitability with $1.2M in adjusted net income. Revenue grew 52% year-over-year to $76.6M, driven by robust 77% growth in high-margin exome and genome testing. The improved adjusted gross margin of 64% reflects operational efficiency and strategic focus on genomic testing. The company's strong cash position of $117.4M and reduced cash burn of $5.0M demonstrate effective financial management. The raised FY2024 guidance to $284-290M in revenue signals confidence in sustained growth trajectory and market expansion.

Medical Research Analyst

The expansion to 30 states for Medicaid coverage of genomic testing represents significant market penetration. The milestone of 700,000 clinical exomes and genomes, with rapid acceleration in testing volume, validates the growing clinical adoption. The GUARDIAN study results published in JAMA, showing 3.7% positive screenings and 92% of cases identifying conditions missed by traditional screening, demonstrates superior clinical utility. The 5-day turnaround time improvement and upcoming Epic integration position GeneDx as a leader in clinical genomics implementation.

Achieved profitability milestone with third quarter adjusted net income¹ of $1.2M

Reported third quarter 2024 revenues² of $76.6M with 77% year-over-year growth of exome and genome test revenue

Expanded third quarter 2024 adjusted gross margins² to 64%

Raising guidance to deliver between $284M and $290M in FY 2024 revenue

GeneDx to host conference call today at 8:30 a.m. ET

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024.

“We delivered 77% growth on exome and genome revenues in Q3 and have reached the point of profitability, a significant milestone in our company’s history,” said Katherine Stueland, CEO of GeneDx. “Our advancements in genomics are redefining the standard of care, setting new industry standards for clinical utility and economic efficiency, and shortening the time to a diagnosis for thousands of families. With an ever-growing number of families eligible for our services, our growth outlook is healthy and sustainable. We continue to bring life-changing impact to the pediatric outpatient and NICU settings, and we are now establishing the foundation for clinically-actionable, responsible, and scalable genomic newborn screening.”

“Once again, our quarterly performance exceeded our top and bottom-line expectations. The third quarter marked our 10th consecutive quarter of cash flow improvement and we achieved positive adjusted net income ahead of our prior target,” said Kevin Feeley, CFO of GeneDx. “With our industry-leading technology and a massive market opportunity ahead, GeneDx will continue to couple financial discipline with strategic investment to accelerate the business and provide answers for even more families in need.”

Third Quarter 2024 Financial Results (Unaudited)^1,2

Revenues

• Revenues from continuing operations grew to $76.6 million, an increase of 52% year-over-year and 11% sequentially.
  • Total company revenues were $76.9 million.
• Exome and genome test revenue grew to $60.0 million, an increase of 77% year-over-year and 18% sequentially.

Exome and genome volume

• Exome and genome test results volume grew to 19,262, an increase of 46% year-over-year and 7% sequentially.
• Exome and genome represented 33% of all test results, up from 23% in the third quarter of 2023 and up from 31% in the second quarter of 2024.

Gross margin

• Adjusted gross margin from continuing operations expanded to 64%, up from 48% in the third quarter of 2023 and up from 62% in the second quarter of 2024.
  • Total company gross margin was 62%.

Operating expenses

• Adjusted total operating expenses were $46.6 million, a decrease of 2% year-over-year and an increase of 4% sequentially.
  • Total GAAP operating expenses were $54.8 million.

Net Income (Loss)

• Adjusted net income improved to $1.2 million, an improvement of 106% year-over-year and 143% sequentially.
  • GAAP net loss was $8.3 million.

Cash burn and cash position

• Total net use of cash was $5.0 million in the third quarter of 2024, an improvement of 88% year-over-year and 17% sequentially.
• Cash, cash equivalents, marketable securities and restricted cash was $117.4 million as of September 30, 2024, inclusive of proceeds of $14.6 million, net of fees, from the issuance of 418,653 shares of Class A common stock in connection with sales pursuant to our “at-the-market” offering during the third quarter of 2024.

GeneDx Full Year 2024 Guidance

GeneDx has updated full year 2024 guidance. Management expects GeneDx to:

• Drive full year 2024 revenues² between $284 and $290 million (previous guidance was between $255 and $265 million);
• Expand full year 2024 adjusted gross margin² profile to at least 62% (previous guidance was at least 60%);
• Use between $60 to $65 million of net cash for full year 2024 (previous guidance was between $65 to $70 million)

1. Adjusted gross margin, adjusted total operating expenses and adjusted net income (loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.
2. Revenue and gross margin results from continuing operations, which we believe are representative of our ongoing business strategy exclude any revenue and cost of goods sold of the exited Legacy Sema4 diagnostic testing business for the current and all comparative periods. Total company results are labeled accordingly and include GeneDx’s continuing operations and the financial impacts of exited Legacy Sema4 business activities for the current and all comparative periods.

Third Quarter 2024 Business Highlights

Driving sustainable growth and expanding access for more patient populations

• Achieved over 700,000 clinical exomes and genomes sequenced, with over 100,000 completed in the last six months alone
• Accelerated adoption of whole exome sequencing (WES) and whole genome sequencing (WGS) coverage by state Medicaid programs, bringing total states covering exome or genome sequencing in the pediatric outpatient setting to 30
  • Indiana - WES and WGS (July 2024)
  • Connecticut - WGS (July 2024)
  • Texas - WGS (September 2024)
  • Florida - WGS (October 2024)
• The Centers for Medicare & Medicaid Services issued “historic guidance” to state Medicaid agencies, underscoring their obligation to provide all medically necessary services under the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit
  • Under EPSDT, every Medicaid-enrolled child under 21 is entitled to services that meet their unique medical needs. This includes diagnostics like exome and genome sequencing - some of the most powerful tools we have to unlock appropriate care, treatments, and crucial support systems for these children.
• Expanded the Epilepsy Partnership Program, a first-of-its-kind patient access program that is increasing access to exome and genome sequencing for pediatric epilepsy patients, by including an additional biopharma partner
• Collaborated with researchers from Wellcome Sanger Institute to release data from the largest and most diverse study to date, with data from more than 30,000 patients, on how recessive genetic changes contribute to developmental disorders in children
  • On September 23, 2024, findings from the study were published in Nature Genetics, showcasing that most new recessive developmental disorder diagnoses lie within known genes.
  • The publication is further evidence of our commitment to the important role of diversity in genomics and belief that serving a more diverse patient population drives more definitive diagnoses for patients of all backgrounds.

Demonstrating genome leadership in the neonatal inventive care unit (NICU)

• Launched improvements to our rapid whole genome sequencing product, including cheek swabs for more accessible sample collection, and shortened turnaround times to as soon as five days
• Progressed initiative to launch Epic Aura in the first half of 2025, which will seamlessly integrate GeneDx exome and genome testing into the ordering and resulting workflows of many of the largest health systems across the country

Leaders in genomic newborn screening (gNBS)

• Conducted more gNBS than any other lab in the United States and successfully executed multi-site implementation strategies across diverse patient populations, positioning GeneDx as the clear leader set to revolutionize the standard approach to NBS
  • On October 8, 2024, data was presented at the International Conference on Newborn Sequencing (ICoNS) showcasing that GeneDx has now provided genomic newborn screenings for more than 14,000 infants through its participation in the groundbreaking GUARDIAN and Early Check research studies. Today, that number exceeds 15,000.
• Revealed limitations of traditional newborn screening methods and showcased the promise of advanced genomic technology to deliver equitable health care for all children
  • On October 24, 2024, findings from the GUARDIAN study were published in JAMA (Journal of the American Medical Association), a leading peer-reviewed medical journal.
  • GUARDIAN goes beyond the typical newborn screening panel of about 60 conditions to now over 450-early onset genetic conditions with established effective interventions.
  • Over the initial 11-month period, 4,000 newborns were enrolled and 3.7% of newborns had positive screenings.
  • By referencing our internal database, one of the largest of its kind enriched for rare disease, we find that the average age of diagnosis for children with these same conditions ranges from 7-11 years.
  • Of the newborns with true positive findings, 92% had a confirmed diagnosis for a condition not included in traditional NBS.
  • The study highlights the wide acceptance of more advanced and modernized NBS, with 72% of families approached for the study consenting to participate.

Webcast and Conference Call Details

GeneDx will host a conference call today, October 29, 2024, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and our market opportunity, including our expected full year 2024 reported revenue guidance, our expectations regarding our adjusted gross margin profile in 2024, and our use of net cash in 2024. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2024 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Volume and revenue in the table below include the combination of the Legacy GeneDx diagnostic business with the data and information business of Legacy Sema4.

Volume & Revenue

		3Q24			2Q24			1Q24			4Q23			3Q23
Volumes
Whole exome, whole genome		19,262				18,017			16,592			15,663			13,216
Hereditary cancer		4,672				5,482			6,868			8,240			8,556
Other panels		35,095				34,204			31,763			33,692			35,861
Total		59,029				57,703			55,223			57,595			57,633
Revenue ($ millions)
Whole exome, whole genome	$	60.0			$	50.7		$	44.0		$	39.2		$	34.0
Hereditary cancer		3.3				3.8			5.5			5.5			4.5
Other panels		13.8				13.3			10.7			11.2			10.6
Data information		(0.5	)			1.1			1.3			2.2			1.3
Total	$	76.6			$	68.9		$	61.5		$	58.1		$	50.4

Unaudited Select Financial Information (in thousands)

	Three months ended September 30, 2024						Three months ended June 30, 2024
	GeneDx		Legacy Sema4		Total		GeneDx		Legacy Sema4		Total
Revenue	$76,622		$252		$76,874		$68,924		$1,590		$70,514
Adjusted cost of services	27,370		—		27,370		26,523		145		26,668
Adjusted gross profit	$49,252		$252		$49,504		$42,401		$1,445		$43,846
Adjusted gross margin %	64.3%		100.0%		64.4%		61.5%		90.9%		62.2%

	Three months ended September 30, 2023
	GeneDx		Legacy Sema4		Total
Revenue	$50,350		$2,953		$53,303
Adjusted cost of services	26,079		225		26,304
Adjusted gross profit	$24,271		$2,728		$26,999
Adjusted gross margin %	48.2%		92.4%		50.7%

	Three months ended September 30, 2024
	Reported				Depreciation and amortization				Stock-based compensation expense				Restructuring costs				Change in FV of financial liabilities			Charges related to business exit			Other				Adjusted
Diagnostic test revenue	$	77,418			$	—			$	—			$	—			$	—		$	—		$	—			$	77,418
Other revenue		(544	)			—				—				—				—			—			—				(544	)
Total revenue		76,874				—				—				—				—			—			—				76,874
Cost of services		29,045				(1,495	)			(174	)			(6	)			—			—			—				27,370
Gross profit		47,829				1,495				174				6				—			—			—				49,504
Gross margin		62.2	%																									64.4	%
Research and development		11,665				(222	)			(537	)			—				—			—			—				10,906
Selling and marketing		17,025				(1,225	)			(394	)			(55	)			—			—			—				15,351
General and administrative		26,145				(2,987	)			(2,531	)			(308	)			—			—			—				20,319
Impairment loss		—				—				—				—				—			—			—				—
Other, net		774				—				—				—				—			—			—				774
Loss from operations		(7,780	)			5,929				3,636				369				—			—			—				2,154
Interest income (expense), net		(843	)			—				—				—				—			—			—				(843	)
Other income (expense), net		264				—				—				—				880			—			(1,327	)			(183	)
Income tax benefit		47				—				—				—				—			—			—				47
Net income (loss)	$	(8,312	)		$	5,929			$	3,636			$	369			$	880		$	—		$	(1,327	)		$	1,175

	Three months ended September 30, 2023
	Reported				Depreciation and amortization				Stock-based compensation expense				Restructuring costs				Change in FV of financial liabilities				Charges related to business exit				Other			Adjusted
Diagnostic test revenue	$	51,955			$	—			$	—			$	—			$	—			$	—			$	—		$	51,955
Other revenue		1,348				—				—				—				—				—				—			1,348
Total revenue		53,303				—				—				—				—				—				—			53,303
Cost of services		28,044				(1,613	)			(75	)			(52	)			—				—				—			26,304
Gross profit		25,259				1,613				75				52				—				—				—			26,999
Gross margin		47.4	%																										50.7	%
Research and development		14,288				(283	)			533				(970	)			—				—				—			13,568
Selling and marketing		16,763				(1,225	)			115				(415	)			—				—				—			15,238
General and administrative		26,099				(5,551	)			(1,004	)			(754	)			—				—				—			18,790
Impairment loss		8,282				—				—				—				—				(8,282	)			—			—
Other, net		2,794				—				—				—				—				(1,014	)			—			1,780
Loss from operations		(42,967	)			8,672				431				2,191				—				9,296				—			(22,377	)
Interest income (expense), net		1,053				—				—				—				—				—				—			1,053
Other income (expense), net		(544	)			—				—				—				(590	)			—				1,134			—
Income tax benefit		172				—				—				—				—				—				—			172
Net loss	$	(42,286	)		$	8,672			$	431			$	2,191			$	(590	)		$	9,296			$	1,134		$	(21,152	)

	Three months ended June 30, 2024
	Reported				Depreciation and amortization				Stock-based compensation expense				Restructuring costs				Change in FV of financial liabilities			Charges related to business exit			Other			Adjusted
Diagnostic test revenue	$	69,439			$	—			$	—			$	—			$	—		$	—		$	—		$	69,439
Other revenue		1,075				—				—				—				—			—			—			1,075
Total revenue		70,514				—				—				—				—			—			—			70,514
Cost of services		27,562				(808	)			(86	)			—				—			—			—			26,668
Gross profit		42,952				808				86				—				—			—			—			43,846
Gross margin		60.9	%																								62.2	%
Research and development		10,902				(211	)			(347	)			(35	)			—			—			—			10,309
Selling and marketing		16,585				(1,225	)			(368	)			(63	)			—			—			—			14,929
General and administrative		25,170				(2,974	)			(2,307	)			(150	)			—			—			—			19,739
Impairment loss		—				—				—				—				—			—			—			—
Other, net		874				—				—				—				—			—			—			874
Loss from operations		(10,579	)			5,218				3,108				248				—			—			—			(2,005	)
Interest income (expense), net		(894	)			—				—				—				—			—			—			(894	)
Other income (expense), net		(17,890	)			—				—				—				4,409			—			13,450			(31	)
Income tax benefit		190				—				—				—				—			—			—			190
Net loss	$	(29,173	)		$	5,218			$	3,108			$	248			$	4,409		$	—		$	13,450		$	(2,740	)

GeneDx Holdings Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)
	September 30, 2024 (Unaudited)				December 31, 2023
Assets:
Current assets:
Cash and cash equivalents	$	57,894			$	99,681
Marketable securities		58,566				30,467
Accounts receivable		38,220				32,371
Due from related parties		260				445
Inventory, net		10,770				8,777
Prepaid expenses and other current assets		20,300				10,598
Total current assets		186,010				182,339
Operating lease right-of-use assets		24,936				26,900
Property and equipment, net		31,452				32,479
Intangible assets, net		162,106				172,625
Other assets (1)		4,336				4,413
Total assets	$	408,840			$	418,756
Liabilities and Stockholders’ Equity:
Current liabilities:
Accounts payable and accrued expenses	$	56,416			$	37,456
Due to related parties		727				1,379
Short-term lease liabilities		3,698				3,647
Other current liabilities		16,501				16,336
Total current liabilities		77,342				58,818
Long-term debt, net of current portion		52,034				52,688
Long-term lease liabilities		60,369				62,938
Other liabilities		13,540				14,735
Deferred taxes		1,054				1,560
Total liabilities		204,339				190,739
Stockholders’ Equity:
Preferred stock		—				—
Class A common stock		2				2
Additional paid-in capital		1,561,493				1,527,778
Accumulated deficit		(1,357,912	)			(1,300,188	)
Accumulated other comprehensive income		918				425
Total stockholders’ equity		204,501				228,017
Total liabilities and stockholders’ equity	$	408,840			$	418,756
(1) Other assets includes $987 thousand of restricted cash as of both September 30, 2024 and December 31, 2023.

GeneDx Holdings Corp. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts)
	Three months ended September 30,								Nine months ended September 30,
		2024				2023				2024				2023
Revenue
Diagnostic test revenue	$	77,418			$	51,955			$	207,961			$	140,440
Other revenue		(544	)			1,348				1,849				4,708
Total revenue		76,874				53,303				209,810				145,148
Cost of services		29,045				28,044				81,618				85,896
Gross profit		47,829				25,259				128,192				59,252
Research and development		11,665				14,288				34,134				46,018
Selling and marketing		17,025				16,763				49,695				45,397
General and administrative		26,145				26,099				73,760				107,129
Impairment loss		—				8,282				—				10,402
Other operating expenses, net		774				2,794				2,622				5,259
Loss from operations		(7,780	)			(42,967	)			(32,019	)			(154,953	)
Non-operating income (expenses), net
Change in fair value of warrants and earn-out contingent liabilities		(880	)			590				(11,390	)			684
Interest (expense) income, net		(843	)			1,053				(2,334	)			2,092
Other income (expense), net		1,144				(1,134	)			(12,300	)			1,668
Total non-operating income (expense), net		(579	)			509				(26,024	)			4,444
Loss before income taxes		(8,359	)			(42,458	)		$	(58,043	)		$	(150,509	)
Income tax benefit		47				172				319				515
Net loss	$	(8,312	)		$	(42,286	)		$	(57,724	)		$	(149,994	)
Weighted average shares outstanding of Class A common stock		27,095,986				25,788,747				26,593,877				23,777,327
Basic and diluted net loss per share, Class A common stock	$	(0.31	)		$	(1.64	)		$	(2.17	)		$	(6.31	)

GeneDx Holdings Corp. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
	Nine months ended September 30,
		2024				2023
Operating activities
Net loss	$	(57,724	)		$	(149,994	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		16,395				27,640
Stock-based compensation expense		6,293				586
Change in fair value of warrants and contingent liabilities		11,390				(684	)
Deferred tax benefit		(319	)			(515	)
Provision for excess and obsolete inventory		137				3,634
Legal reserves		12,123				—
Change in third party payor reserves		737				(6,848	)
Gain on sale of assets		—				(2,954	)
Gain on debt forgiveness		—				(2,750	)
Impairment loss		—				10,402
Other		2,639				1,071
Change in operating assets and liabilities:
Accounts receivable		(5,850	)			10,726
Inventory		(2,131	)			682
Accounts payable and accrued expenses		(7,807	)			(39,913	)
Other assets and liabilities		(1,196	)			(1,372	)
Net cash used in operating activities		(25,313	)			(150,289	)
Investing activities
Consideration on escrow paid for Legacy GeneDx acquisition		—				(12,144	)
Purchases of property and equipment		(2,441	)			(2,874	)
Proceeds from sales of assets		—				3,887
Purchases of marketable securities		(52,725	)			(43,935	)
Proceeds from sales of marketable securities		598				—
Proceeds from maturities of marketable securities		24,955				16,665
Development of internal-use software assets		—				(461	)
Net cash used in investing activities		(29,613	)			(38,862	)
Financing activities
Proceeds from offerings, net of issuance costs		14,589				143,002
Exercise of stock options		247				266
Long-term debt principal payments		(198	)			(2,000	)
Finance lease payoff and principal payments		(1,499	)			(2,133	)
Net cash provided by financing activities		13,139				139,135
Net decrease in cash, cash equivalents and restricted cash		(41,787	)			(50,016	)
Cash, cash equivalents and restricted cash, at beginning of period		100,668				138,303
Cash, cash equivalents and restricted cash, at end of period (1)	$	58,881			$	88,287
Supplemental disclosures of cash flow information
Cash paid for interest	$	6,068			$	1,116
Cash paid for taxes	$	910			$	1,178
Stock consideration paid for purchase of business	$	—			$	6,692
Stock consideration paid pursuant to exercise of Perceptive warrant	$	12,586			$	—
Purchases of property and equipment in accounts payable and accrued expenses	$	2,612			$	1,220
Assets acquired under capital leases obligations	$	689			$	—
(1) Cash, cash equivalents and restricted cash at September 30, 2024 excludes marketable securities of $58.6 million.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241029161441/en/

Investor Relations Contact:

Investors@GeneDx.com



Media Contact:

Press@GeneDx.com

Source: GeneDx

FAQ

What was GeneDx's (WGS) revenue growth in Q3 2024?

GeneDx reported Q3 2024 revenues of $76.6M, representing 52% year-over-year growth and 11% sequential growth.

How many exome and genome tests did GeneDx (WGS) perform in Q3 2024?

GeneDx performed 19,262 exome and genome tests in Q3 2024, a 46% increase year-over-year and 7% sequential growth.

What is GeneDx's (WGS) updated revenue guidance for FY 2024?

GeneDx raised its FY 2024 revenue guidance to between $284M and $290M, up from previous guidance of $255-265M.

How many state Medicaid programs cover GeneDx's (WGS) exome or genome sequencing?

As of Q3 2024, 30 state Medicaid programs cover GeneDx's exome or genome sequencing in the pediatric outpatient setting.